These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 31221612

  • 1. Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton's tyrosine kinase inhibitors.
    Diao Y, Fang X, Song P, Lai M, Tong L, Hao Y, Dou D, Liu Y, Ding J, Zhao Z, Xie H, Li H.
    Bioorg Med Chem; 2019 Aug 01; 27(15):3390-3395. PubMed ID: 31221612
    [Abstract] [Full Text] [Related]

  • 2. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ, Song PR, Dou D, Diao YY, Tong LJ, Zhang T, Xie H, Li HL, Ding J.
    Acta Pharmacol Sin; 2020 Mar 01; 41(3):415-422. PubMed ID: 31316181
    [Abstract] [Full Text] [Related]

  • 3. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
    Teng Y, Lu X, Xiao M, Li Z, Zou Y, Ren S, Cheng Y, Luo G, Xiang H.
    Eur J Med Chem; 2020 Aug 01; 199():112339. PubMed ID: 32402933
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
    Ran F, Liu Y, Yu S, Guo K, Tang W, Chen X, Zhao G.
    Bioorg Chem; 2020 Jan 01; 94():103367. PubMed ID: 31685258
    [Abstract] [Full Text] [Related]

  • 10. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
    Zhang D, Xu G, Zhao J, Wang Y, Wu X, He X, Li W, Zhang S, Yang S, Ma C, Jiang Y, Ding Q.
    Eur J Med Chem; 2021 Dec 05; 225():113724. PubMed ID: 34391034
    [Abstract] [Full Text] [Related]

  • 11. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
    Xue Y, Song P, Song Z, Wang A, Tong L, Geng M, Ding J, Liu Q, Sun L, Xie H, Zhang A.
    J Med Chem; 2018 May 24; 61(10):4608-4627. PubMed ID: 29715023
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C, Pei H, He J, Zhu J, Li W, Niu T, Xiang M, Chen L.
    Eur J Med Chem; 2019 May 01; 169():121-143. PubMed ID: 30875504
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y, Shu Y, Lin J, Chen Z, Xie Q, Bao Y, Lu L, Sun N, Wang Y.
    Eur J Med Chem; 2021 Dec 05; 225():113820. PubMed ID: 34509879
    [Abstract] [Full Text] [Related]

  • 15. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A, Serafini L, Xing W, Czerwieniec G, Steiner B, Wang T, Brendza KM, Lutz JD, Keegan KS, Ray AS, Schultz BE, Sakowicz R, Feng JY.
    Biochim Biophys Acta Gen Subj; 2020 Apr 05; 1864(4):129531. PubMed ID: 31953125
    [Abstract] [Full Text] [Related]

  • 16. HZ-A-005, a potent, selective, and covalent Bruton's tyrosine kinase inhibitor in preclinical development.
    Huang W, Wang S, Zhang Z, Zhang C, Zeng S, Liang M, Shen Z, Liu X.
    Bioorg Chem; 2020 Dec 05; 105():104377. PubMed ID: 33091668
    [Abstract] [Full Text] [Related]

  • 17. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F, Liu Y, Liu M, Zhang D, Wang P, Dong J, Tang W, Zhao G.
    Bioorg Chem; 2019 Aug 05; 89():102943. PubMed ID: 31031018
    [Abstract] [Full Text] [Related]

  • 18. Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.
    Qiu H, Liu-Bujalski L, Caldwell RD, Follis AV, Gardberg A, Goutopoulos A, Grenningloh R, Head J, Johnson T, Jones R, Mochalkin I, Morandi F, Neagu C, Sherer B.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2939-2944. PubMed ID: 30122225
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H, Ali Z, Bender A, Caldwell R, Chen YY, Fang Z, Gardberg A, Glaser N, Goettsche A, Goutopoulos A, Grenningloh R, Hanschke B, Head J, Johnson T, Jones C, Jones R, Kulkarni S, Maurer C, Morandi F, Neagu C, Poetzsch S, Potnick J, Schmidt R, Roe K, Viacava Follis A, Wing C, Zhu X, Sherer B.
    Bioorg Med Chem; 2021 Jun 15; 40():116163. PubMed ID: 33932711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.